Neoadjuvante Camrelizumab plus platinhaltige Chemotherapie vs. Chemotherapie allein bei chinesischen Patienten mit resektablem NSCLC im Stadium IIIA oder IIIB (T3N2)

Lei et al. (Do,) untersuchten diese Fragestellung.

www.synapsesocial.com/papers/69d962b77fca1f84ab684e9b — DOI: https://doi.org/10.1001/jamaoncol.2023.2751

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Adebrelimab (SHR-1316) in Combination With Chemotherapy as Perioperative Treatment in Patients With Resectable Stage II to III NSCLCs: An Open-Label, Multicenter, Phase 1b Trial· 2022 · 33 citations
2. World Medical Association Declaration of Helsinki· 2013 · 28,715 citations
3. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial· 2020 · 501 citations
4. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer· 2016 · 4,602 citations
5. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)· 2008 · 29,244 citations